Concert Pharmaceuticals, Inc. (CNCE): Price and Financial Metrics
CNCE Price/Volume Stats
| Current price | $8.37 | 52-week high | $8.55 |
| Prev. close | $8.36 | 52-week low | $2.66 |
| Day low | $8.35 | Volume | 10,733,200 |
| Day high | $8.55 | Avg. volume | 2,970,800 |
| 50-day MA | $7.49 | Dividend yield | N/A |
| 200-day MA | $5.99 | Market Cap | 401.24M |
CNCE Stock Price Chart Interactive Chart >
Concert Pharmaceuticals, Inc. (CNCE) Company Bio
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel small molecule drugs. The company was founded in 2006 and is based in Lexington, Massachusetts.
Latest CNCE News From Around the Web
Below are the latest news stories about CONCERT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNCE as an investment opportunity.
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia AreataLEXINGTON, Mass., February 15, 2023--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata. |
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout OfferConcert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week. |
5 big deal reports: Sun Pharma’s $576M pact for Concert PharmaBy Davit Kirakosyan |
Why Concert Pharmaceuticals Stock Rocketed Higher This WeekIf all goes according to plan, Concert Pharmaceuticals (NASDAQ: CNCE) will soon cease to be an independent company. The biotech signed a deal to be acquired by a peer; as a result, its share price leaped more than 17% higher on the week, according to data compiled by S&P Global Market Intelligence. The two companies didn't hesitate to point out that this is roughly 33% higher than the latter's 30-day-trailing weighted average share price as of Wednesday, Jan. 18. |
We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. Indeed, Concert Pharmaceuticals... |
CNCE Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 86.83% |
| 5-year | -17.54% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | 85.40% |
| 2021 | -75.08% |
| 2020 | 37.02% |
| 2019 | -26.49% |
Continue Researching CNCE
Want to do more research on Concert Pharmaceuticals Inc's stock and its price? Try the links below:Concert Pharmaceuticals Inc (CNCE) Stock Price | Nasdaq
Concert Pharmaceuticals Inc (CNCE) Stock Quote, History and News - Yahoo Finance
Concert Pharmaceuticals Inc (CNCE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...